Literature DB >> 25922115

Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates.

Ülle Parm1, Tuuli Metsvaht2, Mari-Liis Ilmoja3, Irja Lutsar4.   

Abstract

We hypothesized that the beneficial effects of early enteral compared with parenteral feeding are related to the increased variety of aerobic microorganisms that colonize the gut. Our aim was to describe the relationship, first, between the type of feeding and mucosal colonization and, second, between the type of feeding and the development of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm neonates. In total, 159 neonates aged 72 hours or less with risk factors for early-onset sepsis were recruited to a prospective 2-center study. Rectal swabs were collected on admission and twice per week thereafter. The feeding regimen was recorded for the first 7 days and categorized into total parenteral nutrition (TPN) and 2 regimens of enteral nutrition, that is, breast milk containing regimen (BMCR), for which breast milk constituted at least 11% of the enteral diet, or formula. Herein, 70 neonates received formula, 48 received BMCR, and 41 received TPN; 69 cases of LOS and 15 cases of NEC were observed in 50 neonates. A multiple logistic regression analysis indicated that formula and BMCR were associated with 4- to 5-fold increases in colonization by Gram-negative bacteria (odds ratio [OR], 4.52; 1.87-10.95, and OR, 4.95; 1.90-12.87, respectively) and 5 to 9 times higher odds of colonization by Gram-positive microorganisms (OR, 5.75; 1.89-16.72, and OR, 8.61; 2.52-29.36, respectively) compared with TPN. The only difference between BMCR and the other feeding groups was the higher colonization with Staphylococcus haemolyticus in the latter (formula-OR, 6.24; 1.73-22.50; TPN-OR, 2.75; 1.08-6.97). Compared with BMCR, TPN was associated with an increased odds of LOS (OR, 3.04; 1.02-9.07) and an increased odds of death (19.75; 3.64-107.12) compared with formula. Although early enteral feeding is associated with a higher odds of colonization with opportunistic microorganisms, it should be preferred over TPN whenever feasible, due to the favorable effect on the prevention of LOS.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Gut colonization; Necrotizing enterocolitis; Preterm neonate; Prospective study; Sepsis

Mesh:

Year:  2015        PMID: 25922115     DOI: 10.1016/j.nutres.2015.04.006

Source DB:  PubMed          Journal:  Nutr Res        ISSN: 0271-5317            Impact factor:   3.315


  5 in total

1.  Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsis.

Authors:  Jeffrey R Singer; Emily G Blosser; Carlene L Zindl; Daniel J Silberger; Sean Conlan; Vincent A Laufer; Daniel DiToro; Clay Deming; Ranjit Kumar; Casey D Morrow; Julia A Segre; Michael J Gray; David A Randolph; Casey T Weaver
Journal:  Nat Med       Date:  2019-11-07       Impact factor: 53.440

2.  Nasogastric feeding tubes from a neonatal department yield high concentrations of potentially pathogenic bacteria- even 1 d after insertion.

Authors:  Sandra Meinich Petersen; Gorm Greisen; Karen Angeliki Krogfelt
Journal:  Pediatr Res       Date:  2016-04-11       Impact factor: 3.756

3.  Longitudinal changes in the gut microbiome of infants on total parenteral nutrition.

Authors:  Allison F Dahlgren; Amy Pan; Vy Lam; Kathryn C Gouthro; Pippa M Simpson; Nita H Salzman; T Hang Nghiem-Rao
Journal:  Pediatr Res       Date:  2019-04-09       Impact factor: 3.756

Review 4.  Intestinal dysbiosis and necrotizing enterocolitis: assessment for causality using Bradford Hill criteria.

Authors:  Jennifer B Fundora; Pallabi Guha; Darla R Shores; Mohan Pammi; Akhil Maheshwari
Journal:  Pediatr Res       Date:  2019-06-25       Impact factor: 3.756

Review 5.  Parenteral Nutrition-Associated Liver Disease: The Role of the Gut Microbiota.

Authors:  Monika Cahova; Miriam Bratova; Petr Wohl
Journal:  Nutrients       Date:  2017-09-07       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.